[1]
Vishwanath VA. Fatty Acid Beta-Oxidation Disorders: A Brief Review. Annals of neurosciences. 2016 Mar:23(1):51-5. doi: 10.1159/000443556. Epub 2016 Mar 11
[PubMed PMID: 27536022]
[2]
Rice GM, Steiner RD. Inborn Errors of Metabolism (Metabolic Disorders). Pediatrics in review. 2016 Jan:37(1):3-15; quiz 16-7, 47. doi: 10.1542/pir.2014-0122. Epub
[PubMed PMID: 26729777]
[3]
Hsu HW, Zytkovicz TH, Comeau AM, Strauss AW, Marsden D, Shih VE, Grady GF, Eaton RB. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. 2008 May:121(5):e1108-14. doi: 10.1542/peds.2007-1993. Epub
[PubMed PMID: 18450854]
[4]
Mesbah Z, Sing Ho K, Fitzsimons P, Monavari AA, Mayne PD, Crushell E. Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) in the Irish Paediatric Population. Irish medical journal. 2019 Dec 16:112(10):1016
[PubMed PMID: 32311243]
[5]
Gregersen N, Blakemore AI, Winter V, Andresen B, Kølvraa S, Bolund L, Curtis D, Engel PC. Specific diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in dried blood spots by a polymerase chain reaction (PCR) assay detecting a point-mutation (G985) in the MCAD gene. Clinica chimica acta; international journal of clinical chemistry. 1991 Nov 9:203(1):23-34
[PubMed PMID: 1769118]
[6]
Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, Udvari S, Bross P, Knudsen I, Banas R, Chace DH, Engel P, Naylor EW, Gregersen N. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. American journal of human genetics. 2001 Jun:68(6):1408-18
[PubMed PMID: 11349232]
[7]
Yokota I, Coates PM, Hale DE, Rinaldo P, Tanaka K. Molecular survey of a prevalent mutation, 985A-to-G transition, and identification of five infrequent mutations in the medium-chain Acyl-CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency. American journal of human genetics. 1991 Dec:49(6):1280-91
[PubMed PMID: 1684086]
Level 3 (low-level) evidence
[8]
Kennedy S, Potter BK, Wilson K, Fisher L, Geraghty M, Milburn J, Chakraborty P. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC pediatrics. 2010 Nov 17:10():82. doi: 10.1186/1471-2431-10-82. Epub 2010 Nov 17
[PubMed PMID: 21083904]
[9]
Oerton J, Khalid JM, Besley G, Dalton RN, Downing M, Green A, Henderson M, Krywawych S, Leonard J, Andresen BS, Dezateux C. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England: prevalence, predictive value and test validity based on 1.5 million screened babies. Journal of medical screening. 2011:18(4):173-81. doi: 10.1258/jms.2011.011086. Epub 2011 Dec 13
[PubMed PMID: 22166308]
[10]
Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genetics in medicine : official journal of the American College of Medical Genetics. 2006 Apr:8(4):205-12
[PubMed PMID: 16617240]
[11]
Feillet F, Ogier H, Cheillan D, Aquaviva C, Labarthe F, Baruteau J, Chabrol B, de Lonlay P, Valayanopoulos V, Garnotel R, Dobbelaere D, Briand G, Jeannesson E, Vassault A, Vianey-Saban C, SFEIM (Société française pour l’étude des erreurs innées du métabolisme). [Medium-chain acyl-CoA-dehydrogenase (MCAD) deficiency: French consensus for neonatal screening, diagnosis, and management]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2012 Feb:19(2):184-93. doi: 10.1016/j.arcped.2011.10.025. Epub 2012 Jan 12
[PubMed PMID: 22244319]
Level 3 (low-level) evidence
[12]
Van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, Terada N, Chace DH, Iafolla AK, Ding JH, Millington DS. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. American journal of human genetics. 1993 May:52(5):958-66
[PubMed PMID: 8488845]
[13]
Karaceper MD, Khangura SD, Wilson K, Coyle D, Brownell M, Davies C, Dodds L, Feigenbaum A, Fell DB, Grosse SD, Guttmann A, Hawken S, Hayeems RZ, Kronick JB, Laberge AM, Little J, Mhanni A, Mitchell JJ, Nakhla M, Potter M, Prasad C, Rockman-Greenberg C, Sparkes R, Stockler S, Ueda K, Vallance H, Wilson BJ, Chakraborty P, Potter BK, Canadian Inherited Metabolic Diseases Research Network (CIMDRN). Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. Orphanet journal of rare diseases. 2019 Mar 22:14(1):70. doi: 10.1186/s13023-019-1001-0. Epub 2019 Mar 22
[PubMed PMID: 30902101]
[14]
Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Merritt JL 2nd, Chang IJ. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. GeneReviews(®). 1993:():
[PubMed PMID: 20301597]
[15]
Leonard JV, Dezateux C. Newborn screening for medium chain acyl CoA dehydrogenase deficiency. Archives of disease in childhood. 2009 Mar:94(3):235-8. doi: 10.1136/adc.2007.134957. Epub 2008 Oct 6
[PubMed PMID: 18838415]
[16]
van der Hilst CS, Derks TG, Reijngoud DJ, Smit GP, TenVergert EM. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands. The Journal of pediatrics. 2007 Aug:151(2):115-20, 120.e1-3
[PubMed PMID: 17643759]
[17]
Piercy H, Machaczek K, Ali P, Yap S. Parental Experiences of Raising a Child With Medium Chain Acyl-CoA Dehydrogenase Deficiency. Global qualitative nursing research. 2017 Jan-Dec:4():2333393617707080. doi: 10.1177/2333393617707080. Epub 2017 May 3
[PubMed PMID: 28516128]
Level 2 (mid-level) evidence
[18]
Couce ML, Sánchez-Pintos P, Diogo L, Leão-Teles E, Martins E, Santos H, Bueno MA, Delgado-Pecellín C, Castiñeiras DE, Cocho JA, García-Villoria J, Ribes A, Fraga JM, Rocha H. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency. Orphanet journal of rare diseases. 2013 Jul 10:8():102. doi: 10.1186/1750-1172-8-102. Epub 2013 Jul 10
[PubMed PMID: 23842438]
[19]
Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, Vissing J. Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation. The Journal of clinical endocrinology and metabolism. 2013 Apr:98(4):1667-75. doi: 10.1210/jc.2012-3791. Epub 2013 Feb 20
[PubMed PMID: 23426616]
[20]
Van Hove JL, Kahler SG, Millington DS, Roe DS, Chace DH, Heales SJ, Roe CR. Intravenous L-carnitine and acetyl-L-carnitine in medium-chain acyl-coenzyme A dehydrogenase deficiency and isovaleric acidemia. Pediatric research. 1994 Jan:35(1):96-101
[PubMed PMID: 8134205]
[21]
Allen C, Perkins R, Schwahn B. A retrospective review of anesthesia and perioperative care in children with medium-chain acyl-CoA dehydrogenase deficiency. Paediatric anaesthesia. 2017 Jan:27(1):60-65. doi: 10.1111/pan.13065. Epub 2016 Nov 29
[PubMed PMID: 27896927]
Level 2 (mid-level) evidence
[22]
Rinaldo P, O'Shea JJ, Coates PM, Hale DE, Stanley CA, Tanaka K. Medium-chain acyl-CoA dehydrogenase deficiency. Diagnosis by stable-isotope dilution measurement of urinary n-hexanoylglycine and 3-phenylpropionylglycine. The New England journal of medicine. 1988 Nov 17:319(20):1308-13
[PubMed PMID: 3054550]
[23]
Treem WR, Witzleben CA, Piccoli DA, Stanley CA, Hale DE, Coates PM, Watkins JB. Medium-chain and long-chain acyl CoA dehydrogenase deficiency: clinical, pathologic and ultrastructural differentiation from Reye's syndrome. Hepatology (Baltimore, Md.). 1986 Nov-Dec:6(6):1270-8
[PubMed PMID: 3793003]
[24]
Sim KG, Hammond J, Wilcken B. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clinica chimica acta; international journal of clinical chemistry. 2002 Sep:323(1-2):37-58
[PubMed PMID: 12135806]
[25]
Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Archives of disease in childhood. 1999 May:80(5):459-62
[PubMed PMID: 10208954]
[26]
Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Archives of disease in childhood. 1998 Aug:79(2):116-9
[PubMed PMID: 9797590]
[27]
Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl-CoA dehydrogenase deficiency human genome epidemiology review. Genetics in medicine : official journal of the American College of Medical Genetics. 1999 Nov-Dec:1(7):332-9
[PubMed PMID: 11263545]
[28]
Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet (London, England). 2001 Sep 29:358(9287):1063-4
[PubMed PMID: 11589939]
[29]
Iafolla AK, Thompson RJ Jr, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. The Journal of pediatrics. 1994 Mar:124(3):409-15
[PubMed PMID: 8120710]
[30]
Gramer G, Haege G, Glahn EM, Hoffmann GF, Lindner M, Burgard P. Living with an inborn error of metabolism detected by newborn screening-parents' perspectives on child development and impact on family life. Journal of inherited metabolic disease. 2014 Mar:37(2):189-95. doi: 10.1007/s10545-013-9639-6. Epub 2013 Aug 16
[PubMed PMID: 23949009]
Level 3 (low-level) evidence
[31]
Jager EA, Kuijpers MM, Bosch AM, Mulder MF, Gozalbo ER, Visser G, de Vries M, Williams M, Waterham HR, van Spronsen FJ, Schielen PCJI, Derks TGJ. A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands. Journal of inherited metabolic disease. 2019 Sep:42(5):890-897. doi: 10.1002/jimd.12102. Epub 2019 May 16
[PubMed PMID: 31012112]
Level 2 (mid-level) evidence